vs
Lantheus Holdings, Inc.（LNTH）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是Rapid7, Inc.的1.9倍（$406.8M vs $217.4M），Lantheus Holdings, Inc.净利率更高（13.3% vs 1.4%，领先11.9%），Lantheus Holdings, Inc.同比增速更快（4.0% vs 0.5%），Lantheus Holdings, Inc.自由现金流更多（$81.4M vs $36.4M），过去两年Lantheus Holdings, Inc.的营收复合增速更高（4.9% vs 3.0%）
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
LNTH vs RPD — 直观对比
营收规模更大
LNTH
是对方的1.9倍
$217.4M
营收增速更快
LNTH
高出3.5%
0.5%
净利率更高
LNTH
高出11.9%
1.4%
自由现金流更多
LNTH
多$45.0M
$36.4M
两年增速更快
LNTH
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.8M | $217.4M |
| 净利润 | $54.1M | $3.1M |
| 毛利率 | 59.2% | 68.9% |
| 营业利润率 | 19.0% | 1.0% |
| 净利率 | 13.3% | 1.4% |
| 营收同比 | 4.0% | 0.5% |
| 净利润同比 | 558.8% | 44.1% |
| 每股收益（稀释后） | $0.86 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LNTHRPD
| Q4 25 | $406.8M | $217.4M | ||
| Q3 25 | $384.0M | $218.0M | ||
| Q2 25 | $378.0M | $214.2M | ||
| Q1 25 | $372.8M | $210.3M | ||
| Q4 24 | $391.1M | $216.3M | ||
| Q3 24 | $378.7M | $214.7M | ||
| Q2 24 | $394.1M | $208.0M | ||
| Q1 24 | $370.0M | $205.1M |
净利润LNTHRPD
| Q4 25 | $54.1M | $3.1M | ||
| Q3 25 | $27.8M | $9.8M | ||
| Q2 25 | $78.8M | $8.3M | ||
| Q1 25 | $72.9M | $2.1M | ||
| Q4 24 | $-11.8M | $2.2M | ||
| Q3 24 | $131.1M | $15.4M | ||
| Q2 24 | $62.1M | $6.5M | ||
| Q1 24 | $131.1M | $1.4M |
毛利率LNTHRPD
| Q4 25 | 59.2% | 68.9% | ||
| Q3 25 | 57.9% | 70.2% | ||
| Q2 25 | 63.8% | 70.6% | ||
| Q1 25 | 63.8% | 71.7% | ||
| Q4 24 | 63.5% | 69.5% | ||
| Q3 24 | 63.9% | 70.6% | ||
| Q2 24 | 64.9% | 70.7% | ||
| Q1 24 | 65.4% | 70.3% |
营业利润率LNTHRPD
| Q4 25 | 19.0% | 1.0% | ||
| Q3 25 | 11.4% | 2.7% | ||
| Q2 25 | 23.3% | 1.6% | ||
| Q1 25 | 27.4% | -0.0% | ||
| Q4 24 | 29.1% | 3.4% | ||
| Q3 24 | 35.3% | 6.0% | ||
| Q2 24 | 26.1% | 2.5% | ||
| Q1 24 | 28.8% | 4.7% |
净利率LNTHRPD
| Q4 25 | 13.3% | 1.4% | ||
| Q3 25 | 7.2% | 4.5% | ||
| Q2 25 | 20.8% | 3.9% | ||
| Q1 25 | 19.6% | 1.0% | ||
| Q4 24 | -3.0% | 1.0% | ||
| Q3 24 | 34.6% | 7.2% | ||
| Q2 24 | 15.8% | 3.1% | ||
| Q1 24 | 35.4% | 0.7% |
每股收益（稀释后）LNTHRPD
| Q4 25 | $0.86 | $0.05 | ||
| Q3 25 | $0.41 | $0.15 | ||
| Q2 25 | $1.12 | $0.13 | ||
| Q1 25 | $1.02 | $0.03 | ||
| Q4 24 | $-0.18 | $0.08 | ||
| Q3 24 | $1.79 | $0.21 | ||
| Q2 24 | $0.88 | $0.09 | ||
| Q1 24 | $1.87 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $359.1M | $474.7M |
| 总债务越低越好 | $568.7M | — |
| 股东权益账面价值 | $1.1B | $154.7M |
| 总资产 | $2.2B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.52× | — |
8季度趋势，按日历期对齐
现金及短期投资LNTHRPD
| Q4 25 | $359.1M | $474.7M | ||
| Q3 25 | $382.0M | $407.1M | ||
| Q2 25 | $695.6M | $511.7M | ||
| Q1 25 | $938.5M | $493.5M | ||
| Q4 24 | $912.8M | $521.7M | ||
| Q3 24 | $866.4M | $443.7M | ||
| Q2 24 | $757.0M | $442.6M | ||
| Q1 24 | $718.3M | $411.7M |
总债务LNTHRPD
| Q4 25 | $568.7M | — | ||
| Q3 25 | $567.9M | — | ||
| Q2 25 | $566.8M | — | ||
| Q1 25 | $566.1M | — | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | — |
股东权益LNTHRPD
| Q4 25 | $1.1B | $154.7M | ||
| Q3 25 | $1.1B | $127.2M | ||
| Q2 25 | $1.2B | $90.4M | ||
| Q1 25 | $1.2B | $52.7M | ||
| Q4 24 | $1.1B | $17.7M | ||
| Q3 24 | $1.2B | $-5.1M | ||
| Q2 24 | $1.0B | $-52.6M | ||
| Q1 24 | $945.5M | $-86.4M |
总资产LNTHRPD
| Q4 25 | $2.2B | $1.7B | ||
| Q3 25 | $2.3B | $1.7B | ||
| Q2 25 | $2.1B | $1.6B | ||
| Q1 25 | $2.1B | $1.6B | ||
| Q4 24 | $2.0B | $1.7B | ||
| Q3 24 | $2.0B | $1.6B | ||
| Q2 24 | $1.9B | $1.5B | ||
| Q1 24 | $1.8B | $1.5B |
负债/权益比LNTHRPD
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $90.2M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $81.4M | $36.4M |
| 自由现金流率自由现金流/营收 | 20.0% | 16.8% |
| 资本支出强度资本支出/营收 | 2.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.67× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $354.1M | $146.2M |
8季度趋势，按日历期对齐
经营现金流LNTHRPD
| Q4 25 | $90.2M | $37.6M | ||
| Q3 25 | $105.3M | $39.0M | ||
| Q2 25 | $87.1M | $47.5M | ||
| Q1 25 | $107.6M | $29.8M | ||
| Q4 24 | $157.7M | $63.8M | ||
| Q3 24 | $175.1M | $44.0M | ||
| Q2 24 | $84.7M | $32.9M | ||
| Q1 24 | $127.2M | $31.1M |
自由现金流LNTHRPD
| Q4 25 | $81.4M | $36.4M | ||
| Q3 25 | $94.7M | $34.8M | ||
| Q2 25 | $79.1M | $46.6M | ||
| Q1 25 | $98.8M | $28.4M | ||
| Q4 24 | $141.4M | $62.6M | ||
| Q3 24 | $159.3M | $42.6M | ||
| Q2 24 | $73.5M | $32.6M | ||
| Q1 24 | $119.0M | $30.4M |
自由现金流率LNTHRPD
| Q4 25 | 20.0% | 16.8% | ||
| Q3 25 | 24.7% | 16.0% | ||
| Q2 25 | 20.9% | 21.8% | ||
| Q1 25 | 26.5% | 13.5% | ||
| Q4 24 | 36.1% | 28.9% | ||
| Q3 24 | 42.0% | 19.9% | ||
| Q2 24 | 18.7% | 15.7% | ||
| Q1 24 | 32.2% | 14.8% |
资本支出强度LNTHRPD
| Q4 25 | 2.2% | 0.5% | ||
| Q3 25 | 2.8% | 1.9% | ||
| Q2 25 | 2.1% | 0.4% | ||
| Q1 25 | 2.3% | 0.6% | ||
| Q4 24 | 4.2% | 0.5% | ||
| Q3 24 | 4.2% | 0.6% | ||
| Q2 24 | 2.8% | 0.1% | ||
| Q1 24 | 2.2% | 0.3% |
现金转化率LNTHRPD
| Q4 25 | 1.67× | 12.01× | ||
| Q3 25 | 3.79× | 3.97× | ||
| Q2 25 | 1.11× | 5.70× | ||
| Q1 25 | 1.47× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | 1.34× | 2.85× | ||
| Q2 24 | 1.36× | 5.03× | ||
| Q1 24 | 0.97× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
